1. Pink Sheet
  2. >>Geography
  3. >>Europe

Dengue Vaccine Qdenga & Nine Drugs Win EMA Thumbs Up

 
• By Neena Brizmohun

The European Medicines Agency has delivered its verdict on marketing applications for a raft of new medicines.

New drugs will soon be approved for use in the EU • Source: Shutterstock

The European Medicines Agency has recommended pan-EU marketing approval for 10 new products, including Qdenga, Takeda Pharmaceutical’s dengue vaccine, which the agency also simultaneously recommended for approval in low- and middle-income non-EU countries.

Qdenga (dengue tetravalent vaccine (live, attenuated)) is for the prevention of dengue virus serotypes 1, 2, 3 and 4 in people from four years of age

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.